Skip to content
Open access

Remote digital cognitive assessment in a trial‐ready Alzheimer's disease cohort: A scalable approach for early intervention studies

Jul 2026 · Alzheimer's & Dementia · Vol 12 · 1 citation · 42 references
Medicine

TL;DR

High‐frequency remote cognitive assessment is feasible, reliable, and valid in a relatively young international ADAD cohort, supporting its integration into early‐intervention studies.

Abstract

ABSTRACT INTRODUCTION Early detection of cognitive decline in Alzheimer's disease (AD), particularly in preclinical stages, is critical for evaluating therapeutic interventions. Traditional cognitive assessments often require lengthy in‐person visits, and may therefore limit scalability for younger, trial‐ready populations for primary and secondary prevention studies. We evaluated the feasibility, reliability, and validity of high‐frequency remote digital cognitive assessments in individuals with autosomal dominant AD (ADAD).

Methods

One hundred twenty‐three mutation carriers and non‐carriers from the Dominantly Inherited Alzheimer Network Trials Unit from 20 international sites (Ages 19–66 years) completed remote assessments via personal smartphones, prompted four times daily for 7 days (≈ 3 minutes per session), and conventional in‐clinic cognitive testing at baseline. Adherence, between‐person reliability, test–retest reliability (intraclass correlation coefficients [ICCs]), construct validity (confirmatory factor analysis), and sensitivity to clinical disease progression were evaluated.

Results

Remote measures demonstrated excellent reliability (ICCs > 0.90 after just 10 sessions) and strong construct validity, with tasks loading onto memory, attention, and executive function domains. A composite of the remote tests slightly outperformed a traditional composite at separating mutation carriers from non‐carriers. Average adherence to the study protocol was 42%, lower that observed in previous studies of older adults.

Discussion

High‐frequency remote cognitive assessment is feasible, reliable, and valid in a relatively young international ADAD cohort. This approach offers substantial utility for clinical trials, including improved accessibility and enhanced reliability, supporting its integration into early‐intervention studies.

Read PDF

Similar papers

Open access Sep 2026

Feasibility of remote self-administered cognitive assessment in an Alzheimer’s disease treatment clinic

Introduction: Remote cognitive assessments offer an accessible, scalable way to support clinical characterization and longitudinal monitoring of cognition. This study evaluates the feasibility of implementing Mayo Test Drive (MTD), a remote, self-administered digital cognitive assessment, within a specialized clinic fo...

Alyssa N. Kaser, J. L. Stricker, Morgan A. Hughes et al. · 0 citations
Open access Sep 2026

Diagnostic accuracy of remote self-administered digital cognitive assessment by clinical diagnosis and Alzheimer’s disease PET imaging biomarkers

INTRODUCTIONCognitive characterization is increasingly important for Alzheimers disease treatment decisions, highlighting the need for scalable cognitive assessment. We evaluated the diagnostic accuracy of a remote self-administered cognitive screening battery, Mayo Test Drive (MTD), across clinically and biologically...

N. Stricker, Elizabeth A. Boots, Rita L. Taylor et al. · 0 citations
Open access Sep 2026

Comparative Value of Cognitive and Functional Assessments for Predicting 24-Month Progression from Mild Cognitive Impairment to Alzheimer’s Disease: An ADNI Cohort Study

Episodic memory demonstrated the strongest predictive performance among the individual assessment domains evaluated of 24-month progression from MCI to AD, with functional assessment providing substantial complementary value.

Sophie Choe · 0 citations
Review Sep 2026

Mobile application-based interventions for subjective memory decline and mild cognitive impairment: A systematic review.

BackgroundSubjective cognitive decline (SCD) and mild cognitive impairment (MCI) are early clinical markers along the continuum from normal aging to dementia. Both conditions are associated with an elevated risk of progression to Alzheimer's disease and related dementias. With SCD affecting up to 25% and MCI up to 25.2...

Cynthia Zou, Ana-Sophia Chung, Milly Tadigiri et al. · 0 citations
Open access Jul 2026

Comparative analyses of Alzheimer's disease blood biomarkers and cognitive domains

AD blood‐based biomarker–cognition associations were domain‐differentiated and context‐dependent: Concurrent associations did not reliably indicate associations with cognition 6 years later, and only p‐tau181 showed formal evidence of relative memory‐versus‐executive selectivity.

Deirdre M. O'Shea, James E. Galvin · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.